Arcadia Biosciences, Inc. 8-K

What Happened Arcadia Biosciences, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 in a press release dated March 26, 2026. The company furnished the press release and its annual financial information tables as Exhibits 99.1 and 99.2 to the Form 8‑K; the filing was signed by CEO Thomas J. Schaefer.

Key Details

• Event reported under Item 2.02 (Results of Operations and Financial Condition) on Form 8‑K filed March 26, 2026.
• Period covered: fourth quarter and full year ended December 31, 2025.
• Exhibits: 99.1 — press release titled "Arcadia Biosciences Announces Fourth‑Quarter and Full Year 2025 Financial Results and Business Highlights"; 99.2 — full year 2025 financial information tables.
• The furnished materials are expressly stated not to be "filed" under Section 18 of the Exchange Act (and not subject to certain liabilities under the Securities Act).

Why It Matters This is the company’s official public release of its quarterly and annual results; investors should review the attached press release and financial tables to see reported revenue, earnings, cash position, and any management commentary on business trends or outlook. Note the company’s statement that the furnished materials are not deemed “filed,” which affects legal liabilities but does not change the need to evaluate the disclosed financial information. For audited and legally filed financial statements or any forward‑looking guidance, investors should also watch for the company’s periodic reports (e.g., 10‑K or 10‑Q).